Haemonetics Corp. (HAE) Tops Q3 EPS by 6c; Affirms FY12 EPS Outlook
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $108.40 +0.74%
EPS Growth %: 0.0%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: 0.0%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q3 EPS of $0.86, $0.06 better than the analyst estimate of $0.80. Revenue for the quarter came in at $191.2 million versus the consensus estimate of $186.21 million.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Premarket movers: Xenon sinks on trial pause, Netflix hit by downgrade
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
